Jukka Westermarck and his group received the Elias Tillandz -prize
Prof. Jukka Westermarck and his group received the Elias Tillandz -prize for the best publication of the year for his ground-breaking study on that reveals the druggability of type-2A phosphatase, which has been largely regarded as a non-druggable cancer target. Link to study.
Warmest congratulations to the whole team!
Read more:
Recent Posts
-
Season’s Greetings & Happy 2026!
Season’s Greetings & Happy 2026! From everyone at Turku Bioscience. Riitta Lahesmaa,Director of Turku Bioscience Read moreDecember 23, 2025
-
The Sigrid Jusélius senior researcher posts grant to Carlos Rogerio Figueiredo
The Sigrid Jusélius Foundation has awarded a four-year senior researcher grant of €700,000 to our Read moreDecember 15, 2025
-
Guillaume Jacquemet awarded the 2025 Chancellor’s Prize
Guillaume Jacquemet, a Group Leader at our centre, has been awarded the Chancellor’s Prize for Read moreDecember 15, 2025
-
New Funding for our Centre’s Researchers
Warm congratulations to all for their funding! Cancer Foundation Finland Project grants Travel grants The Read moreDecember 12, 2025
-
Sami Ventelä and Jukka Westermarck recognized by Medical Association Duodecim for their influential work.
Medical association Duodecim selects each year persons that have been most influential in the field Read moreDecember 11, 2025
-
Our affiliated Group Leader Rafa Najumudeen secures ERC Consolidator Grant
The European Research Council (ERC) has awarded a Consolidator Grant to our affiliated Group Leader, Read moreDecember 9, 2025